Introduction {#S0001}
============

Infectious diseases are caused by viruses, fungi, bacteria, and parasites. They infect a lot of people and cause numerous deaths annually, especially in developing countries.[@CIT0001],[@CIT0002] Factors such as increasing mobility of humans, climate change, increase in the exchange of goods and services across different borders, and globalisation has aided infectious diseases transmission and dynamics across the world.[@CIT0003],[@CIT0004]

Disease diagnosis plays critical roles in patient care. It helps with knowing the actual etiological agent in cases of infection, while also making it possible to identify infections arising from previously unknown, as well as new pathogens. With proper identification of the causal agent, effective therapy can be instituted and monitored, and efficient surveillance systems can be established to control disease spread. Although infectious disease patterns are changing rapidly, proper diagnosis is one way to monitor the changing trend continuously.[@CIT0005]

Absence of proper, efficient and accurate diagnosis of infectious diseases portend severe problems for healthcare. Accurate and rapid diagnosis of a disease is crucial in determining what kind of treatment should be administered by health workers. Some avoidable deaths have occurred where health workers administered the wrong treatments as a result of the wrong diagnosis. In a study by Lu et al[@CIT0006] 25.8% (32/124) avoidable deaths were recorded in the emergency department of a health facility over three years, seven of which were due to misdiagnosis and eight due to delayed diagnosis. In another multi-centre study of mortality associated with misdiagnosis, the researchers reported misdiagnosis in 11.6% (113/974) patients with 15% in-hospital mortality.[@CIT0007] In some other instances, it is not uncommon for treatment to commence later than is required for the most efficient clinical intervention as a result of inadequate testing facilities,[@CIT0008] delays in diagnosis of disease[@CIT0009] and slow diagnostic process.[@CIT0010] For instance, the use of stool culture in the diagnosis of *Clostridium difficile* diarrhoea takes 2--3 days to complete, thereby delaying commencement of treatment.[@CIT0010] When a patient gets treated with antibiotics without a proper and accurate diagnosis of causal agents involved, the outcome could be ineffective and antimicrobial resistance could result, leading to pathogens becoming more difficult to treat than they were previously. This problem results from the overuse of effective antimicrobial agents and drugs,[@CIT0011] which are becoming fewer by the day. Not less than half the population of adults and children who suffer upper respiratory tract infection are treated with antibiotics, even though the majority of such illnesses result from viral infections[@CIT0012]--[@CIT0014] Antimicrobial resistance has recently become a serious problem, with increasing magnitude across the globe.[@CIT0011]

From the simple microscope invented by Antonie van Leeuwenhoek to the present use of sophisticated technologies, identification of pathogens has evolved greatly. This evolution has been made possible by advancements in the study and understanding of different scientific fields, including Molecular Biology. Hence, the diagnosis of diseases can now be conducted from various sample types.[@CIT0005] Available automated systems used for biochemical testing such as VITEK 2 (bioMérieux, Marcy l'Etoile, France) and Analytical Profile Index 20 (bioMérieux, Marcy l'Etoile, France) report low sensitivity, as identification is phenotypic. The cost also makes it unaffordable in resource-constrained areas.[@CIT0015] Simple and rapid identification techniques have been established over time, which base identification on the molecular characteristics of microbes. NAAT is an essential molecular identification technique applied in many aspects of healthcare such as disease diagnosis and investigations into genetic disorders.[@CIT0016] These methods are sensitive, specific and require a shorter time to complete than the older culture methods. Polymerase chain reaction (PCR) which pioneered the revolution in molecular diagnosis, was developed in 1983 by Kary Mullis.[@CIT0017],[@CIT0018] Since then, various versions of PCR have been developed, such as quantitative, nested, real-time, multiplex, and immunocapture PCR. The advent of the PCR appeared to ease pathogen identification, but its cumbersome procedure, sophisticated equipment requirement, operation at varying temperatures and the extent of expertise needed for its operation has limited its usage.[@CIT0017],[@CIT0019] One advantage of PCR-based assays, however, is that sequencing tools can be used to analyse the resulting amplification products, availing much more information about the organism.[@CIT0020] Interestingly, molecular methods have been used to identify some organisms that cannot be cultured in the laboratory. For instance, the Hepatitis C virus (HCV) and *Tropheryma whipplei* were first detected using molecular methods. The advent of nucleotide sequencing and pyrosequencing have also assisted in both the identification of pathogens and understanding the genetic relatedness of pathogens.[@CIT0005] Real-time PCR has facilitated nucleic acid quantification through fluorescent-labelled probes and has been applied in the quantification of pathogens with reported accuracy, precision, ease of standardisation and rapidity. Despite this, real-time PCR still requires expensive instrumentation and special expertise to perform and is hence, not within reach of resource-constrained societies.[@CIT0021] Real-time PCR involves the use of techniques that requires trained personnel with adequate knowledge of its usage and interpretation and as such might not be easily applicable in all settings.[@CIT0017],[@CIT0019]

Though many diagnostic methods now exist that facilitate more accurate diagnosis of disease agents, improvement of existing methods with capabilities for higher rapidity, accuracy, ease of use and less cost is still a crucial need. Point of care diagnosis of disease, which does not require sophisticated equipment or visiting the hospital environment, will enhance healthcare and surveillance if they are made simple enough to be used even with minimal training. This review takes a look at some techniques applied in infectious diseases diagnosis and highlights the important types of isothermal methods currently in use. Future directions of these simpler methods have been highlighted to encourage the development of simpler technologies, which will greatly aid healthcare delivery, especially in resource-constrained areas.

Isothermal Amplification Methods {#S0002}
================================

One reason why nucleic acid amplification appears to be cumbersome is the need for initial extraction of the pathogen's nucleic acid, amplification of the sequence of interest in the nucleic acid, and then analysis of products obtained,[@CIT0005] especially when the use of gel electrophoresis is involved. Less cumbersome and more straightforward non-PCR based isothermal techniques such as Nucleic Acid Sequence Based Amplification (NASBA),[@CIT0022] Sequence Mediated Amplification of RNA Technology (SMART),[@CIT0023] Strand Displacement Amplification (SDA),[@CIT0024] Loop-mediated Isothermal Amplification (LAMP)[@CIT0016] and most recently the Multiple Cross Displacement Amplification (MCDA)[@CIT0025] have been developed ([Table 1](#T0001){ref-type="table"}). These methods operate at a uniform temperature without the need for variation during the process, therefore eliminating the use of thermocyclers. Also, real-time readings of amplification are possible with these methods, and amplified products detected by measuring turbidity or by visual inspection for colour change. This capability eliminates the need for gel electrophoresis. IA methods could become more popular than PCR soon, owing to their low energy requirement and simplicity which allows for their possible integration into simple, compact systems.[@CIT0026] IA methods differ from one another in features such as the number of primers and enzymes, the temperature of amplification and template types used. Some POC platforms based on IA have been developed with some already commercialised ([Table 2](#T0002){ref-type="table"}).Table 1Summary of Some Clinical Studies with IA MethodsDiagnosisSpecimen/SourceIA usedGS UsedIncubationTTR (Min)LODSpecificity (%)Sensitivity (%)PPVNPVRef.VTEC *Escherichia coli*Beef & bovine faecesmLAMPPCRReal-time fluorometer\<402.5--3.5 Log cfu/mL10050NCNC\[[@CIT0033]\]*Clostridium difficile*StoolHDACytotoxicity testND301.25x10^−2^pg100100100100\[[@CIT0064]\]*Plasmodium* speciesHuman blood & salivaRCALight-microscopyMicrofluidic device150\<parasite/μL100100100100\[[@CIT0140]\]Human papilloma virus 16 & 18Cervical mucus exfoliated cellsRCAHC2 (Digene) testqPCR machineND26 ng of gDNA100100100100\[[@CIT0128]\]*Mycobacterium tuberculosis* complex, *Mycobacterium avium*, and *Mycobacterium intracellulare*SputumLAMPAmplicorND35-605-50 copies10050NCNC\[[@CIT0034]\]*Vibrio parahemolyticus* and *Salmonella* sppReference strainsRT LAMPPCRND15-6010 pg/μ L100NCNCNC\[[@CIT0035]\]*Acinetobacter baumannii*SputumRT LAMPPCRPortable fluorescence reader601000 cfu/mL75.098.998.998.2\[[@CIT0036]\]*Porphyromonas gingivalis* and *Aggregatibacter actinomycetemcomitans*Subgingival plaque and salivaLAMPPCRHeating block30-601 ngNCNCNCNC\[[@CIT0037]\]Species of *Candida* and *Trichosporon*MilkLAMPNCReal-time turbidimeter\<40-6010°--10^3^ cells mL^−1^100NCNCNC\[[@CIT0038]\]Influenza A and B virusNasopharyngeal\
(NP) swabsLAMPqPCRReal-time fluorometer6-221*ge*10097.9NCNC\[[@CIT0039]\]*Plasmodium falciparum, P. vivax, P. malariae and P. ovale*BloodRT LAMPNested PCR/MicroscopyPortable fluorescence reader15-601-100p/μL96.791.7NCNC\[[@CIT0040]\]*Salmonella enteritidis* and other speciesLiquid egg and brothLAMPPCRThermal cycler\<602.2--625 cells/test tube100NCNCNC\[[@CIT0042]\]O9 group of SalmonellaChickensLAMPPCRReal-Time Turbidimeter3010^3^ cfu/mL10091.791.792.3\[[@CIT0043]\]Verotoxigenic *Escherichia coli* O157 and O26Ground beef and alfalfa sproutsRT LAMPImmunomagnetic separationReal-Time Turbidimeter60400 cfu/mL99.2^\#^100^\#^NCNC\[[@CIT0044]\]*Escherichia coli*UrineLAMPCultureHeating block6010 copies/reaction10091.710097\[[@CIT0046]\]Heat-labile 1 & heat-stable I enterotoxigenic Escherichia coli (ETEC)StoolRT LAMPPCRReal-Time Turbidimeter12-424-40 cfu/test100\*NCNCNC\[[@CIT0045]\]*Campylobacter jejuni* and *Campylobacter coli*StoolLAMPCultureReal-Time Turbidimeter19-551.4 & 1.2 cfu per test tube96.681.392.990.3\[[@CIT0047]\]*Clostridium difficile*StoolLAMPToxigenic\
culture (TC)Illumipro-10 incubator/reader150NC99959898\[[@CIT0174]\]*Clostridium difficile*StoolLAMPToxigenic\
culture (TC)Illumipro-10 incubator/reader60ND91.191.891.899.1\[[@CIT0175]\]*Clostridium difficile*StoolHDAPCR/EIAWater bath/heat block\<15010^4^cfu/g/20 copies per test100100100100\[[@CIT0176]\]*Trachomonas. vaginalis*Urine & vaginal swabHDASaline microscopy/cultureSolana^®^ instrument45ND98.2--98.695.0--99.2NCNC\[[@CIT0177]\]Group A *Streptococcus*Throat swabHDACultureSolana instrumentNDND97.298.290.299.5\[[@CIT0178]\]*Staphylococcus aureus/mecA* geneBlood culture mediumHDAStaphPlex systemHeating block/water bath902 x 10^4^ cells/mL100/98100/100100/90.5100/100\[[@CIT0179]\]Methicillin-resistant *Staphylococcus aureus*Swabs from different body sitesSMARTPCRHeat block1102 x 10^5^ and 10^6^ cfu/assay98.658.194.784.0\[[@CIT0069]\]Human CytomegalovirusCerebrospinal FluidNASBANested PCR/viral cultureHeating block/water bathWithin one dayBetween 1 and 5 copies10010010097.0\[[@CIT0084]\]HIV-1BloodNASBAAMPLICORHeating block/water bathND\<10^2^ copies/mL100100NCNC\[[@CIT0079]\]*Legionella pneumophila*Sputum and bronchoalveolar lavage (BAL)LAMPPCRNDND\<1.15 pg/µL100100100100\[[@CIT0180]\]*bla*~KPC~ and *bla*~NCM-1~*E. coli, Klebsiella pneumonia* and *Acinetobacter baumannii*LAMPPCRND120-180ND100100100100\[[@CIT0032]\][^1] Table 2Commercial Diagnostic Kits, Platforms and Systems Using IA TechniquesProduct NameIA Method UsedTarget Pathogen/PurposeTypeApplicationCompany nameReferencesAlethiaLAMP*C. difficile*\
Herpes simplex virus (HSV) type 1 & 2\
Cytomegalovirus\
*Streptococcus agalactiae*\
*Mycoplasma pneumonia*\
*Bordetella pertussis*\
*Streptococcus pyogenes*\
*Plasmodium* sppKitClinical DiagnosisMeridian Bioscience; Cincinnati, OH, USA\[[@CIT0174],[@CIT0175],[@CIT0181],[@CIT0182]\]3M™ Molecular Detection SystemLAMP*Campylobacter*\
*Salmonella*\
*Listeria monocytogenes*\
*Cronobacter*\
*E. coli*KitClinical detection3M, USA\[[@CIT0183],[@CIT0184]\]TB-LAMP\
Malaria-LAMP\
Loopamp MTBC Detection Kit^®^LAMP*Mycobactrium tuberculosis*\
*Plasmodium vivax, Plasmodium falciparum and Plasmodium pan species*\
*Mycobacterium tuberculosis*KitClinical DiagnosisHuman Diagnostics Worldwide\[[@CIT0185],[@CIT0186]\]Eazyplex^®^LAMPVarious bacterial pathogensKitsClinical diagnosisAmplex Diagnostics GmbH\[[@CIT0187]--[@CIT0190]\]NuclisensEasyq^®^ HIV-1 v2.0NASBAHIVAutomated assayHIV-1 RNA QuantificationBiomerieux\[[@CIT0191]\]BD ProbeTec™SDA*Chlamydia trachomatis*\
*Neisseria gonorrhoeae*KitClinical diagnosisBD Diagnostics, USA\[[@CIT0192]--[@CIT0194]\]Aptima^®^ assaysTMA*Chlamydia trachomatis*\
*Neisseria gonorrhoeae*\
*Mycoplasma genitalium*\
*Trichomonas vaginalis*\
*HSV 1 & 2*\
Zika Virus\
HIV-1\
HBV\
HCV\
HPVKitDiagnosis and quantificationHologic^®^ Inc., USA\[[@CIT0195]--[@CIT0197]\]AmpliVue assay and Solana assayHDA*Bordetella pertussis*\
*Trichomonas vaginalis*\
*Clostridium difficile*\
Herpes simplex virus type 1 & 2\
Varicella-zoster virus\
Group B Streptococcus\
*Bordetella parapertussis*\
*Streptococcus pyogenes*\
Influenza A\
Influenza B respiratory syncytial virus\
Human metapneumovirus\
*Streptococcus dysgalactiae*KitClinical diagnosisQuidel Corporation, USA\[[@CIT0177],[@CIT0178],[@CIT0198]\]Genie II & Genie IIIIsothermal DNA/RNA amplification by LAMPTarget amplification and fluorescence measurementReal-time InstrumentPOCOptiGene, United Kingdom\[[@CIT0199],[@CIT0200]\]T16-ISO InstrumentIsothermal DNA/RNA amplification by RPATarget amplification and fluorescence measurementReal-time InstrumentPOCTwistDx Limited, United Kingdom\[[@CIT0107],[@CIT0201]\]ESEQuant TS2 (2.2--2.x)Isothermal DNA/RNA amplificationTarget amplification and fluorescence measurementReal-time InstrumentPOCQiagen, Venlo, Netherlands\[[@CIT0141]\]LA320, LA350, LA500Isothermal DNA/RNA amplification by LAMPTarget amplification and fluorescence measurementReal-time InstrumentPOCEiken Chemical Company Ltd, Japan\[[@CIT0202]\]HumaLoop M incubatorIsothermal DNA/RNA amplification by LAMPTarget amplification and fluorescence measurementReal-time InstrumentPOCHuman Diagnostics, Wiesbaden, Germany\[[@CIT0141]\][^2]

Loop-Mediated Isothermal Amplification (LAMP) {#S0002-S2001}
---------------------------------------------

LAMP is an IA method first developed and reported in the year 2000.[@CIT0016] LAMP gained acceptance because it is highly specific, sensitive and rapid[@CIT0027] coupled with its isothermal nature, the use of high strand displacing DNA polymerase enzyme of *Bacillus stearothermophilus* (Bst), all facilitating amplification of minimal number of DNA into as much as 10^9^ copies within one hour.[@CIT0016] LAMP assay requires four specific primers. These include the inner and outer primers that recognise a total of six different sequences of a DNA. Backward Inner Primer (BIP) and Forward Inner Primer (FIP) make up the inner primers. The assay also includes Forward Loop (LF) and Backward Loop (LB) primers for more rapid amplification ([Figure 1](#F0001){ref-type="fig"}). Similarly, Backward outer (B3) and Forward outer (F3) make up the outer primers. Sense and antisense sequences found on FIP (F2 and F1c) and BIP (B2 and B1c) interact with the initiation points for LAMP.[@CIT0016] The LAMP procedure consists of a single amplification period at between 60 to 65°C for 1 hr.Figure 1Schematic illustration of LAMP. The reaction begins with annealing of the FIP and its extension by polymerase enzyme to form a new strand of DNA which is displaced by extension of F3 (non-cyclic phase). The new strand forms a loop at the 5ʹ end with compliment sequences at F1 and F1c. BIP also anneals, and a similar process as of FIP releases another new strand that forms a double stem-loop structure at both ends. A new double stem-loop DNA with a sequence complementary to the first strand and another stem-loop with double the length of the previous one is formed subsequently from self-primed extension by the DNA strand, and by annealing of FIP and BIP coupled with extensions and displacements. As products from subsequent steps get involved in the reaction, DNA structures of different sizes bearing inverted repeats on the same strand result with multiple loops formed as a result of alternately repeated sequences on the same strand. Reproduced from Notomi T, Okayama H, Masubuchi H, et al. Loop-mediated isothermal amplification of DNA. *Nucleic Acids Res*. 2000;28(12):E63--E63.[@CIT0016]

Nucleic acid amplification by LAMP begins with the binding of the sense strand of FIP (F2) to the F2c of the target region, resulting in the synthesis of a complementary strand ([Figure 1](#F0001){ref-type="fig"}). This strand is displaced when F3 binds to F3c of the target sequence and initiates synthesis, resulting in a FIP-linked displaced strand with a loop-structured end. BIP initiates synthesis of another strand using the FIP-linked strand as a template. Displacement of the synthesised strand through B3-primed synthesis results in dumb-bell structured material which converts into a stem-loop by self-priming. The second stage utilises the stem-loop material in a series of repeated amplification cycles to yield a vast number of amplified strands of various stem lengths from the target sequence.[@CIT0016] Hence, amplification occurs by two types of repeated cycles around the formed loop: self-primed elongation at the 3ʹ end of the template via the stem-loop structure, and elongation occasioned by the inner primers around the loop.[@CIT0017]

Detection of products is by gel electrophoresis, fluorescence detection or directly by turbidity due to magnesium pyrophosphate that accumulates as an end product of amplification. Intercalating fluorescent dyes like Pico and SYBR Green are applied to enhance direct visual detection of amplified products.[@CIT0028]--[@CIT0030] Amplified products form bands which appear like a ladder on agarose gel electrophoresis.[@CIT0017],[@CIT0031]

LAMP has the capacity for incorporation into assays for medical investigation, genetic testing, environmental testing and rapid testing of food products, especially in resource-constrained environments.[@CIT0017] LAMP has found application in detecting resistance genes such as *bla*~KPC~ and *bla*~NDM-1~ in *E. coli, Klebsiella pneumonia* and *Acinetobacter baumannii*[@CIT0032] as well as identification of bacteria like *E. coli*,[@CIT0033] Mycobacteria,[@CIT0034] *Vibrio parahemolyticus, Salmonella* spp[@CIT0035] and *A. baumannii*.[@CIT0036] LAMP with a detection limit of 1ng has also been successfully used for rapid detection of *Porphyromonas gingivalis* and *Aggregatibacter actinomycetemcomitans*, both of which cause periodontitis in humans.[@CIT0037] LAMP assays for detecting yeasts,[@CIT0038] influenza viruses[@CIT0039] and *Plasmodium* have been developed.[@CIT0040] Different companies have also designed commercial LAMP kits ([Table 2](#T0002){ref-type="table"}) for the detection of Salmonella,[@CIT0041]--[@CIT0043] verotoxin-producing *Escherichia coli*[@CIT0044]--[@CIT0046] and Campylobacter.[@CIT0047]

Different studies have reported high specificity and sensitivity of LAMP assay. In a systematic review of 16 studies (6,979 samples) which evaluated the accuracy of LAMP in detecting *Clostridium difficile* disease in humans, LAMP was reported more sensitive and specific than anaerobic toxigenic culture (TC).[@CIT0048] TC (sensitivity of 90--100%, specificity of 98--100%) is one of the reference tests used for evaluation of novel testing methods for *Clostridium difficile*.[@CIT0049],[@CIT0050] Two different publications reported higher sensitivity of LAMP than PCR designed for *Salmonella enterica* with egg constituents unable to inhibit the assay.[@CIT0041],[@CIT0042]

Researchers are now developing miniaturised versions of the LAMP assay. A reported study which used a commercial poly(methyl methacrylate) (PMMA) microchip with sample cross channel with a width of 100µm and depth of 30µm, achieved amplification, detection and analysis of a prostate-specific antigen gene using a single device.[@CIT0051] The study used LAMP for amplification, electrophoresis for detection of amplified products and analysis by visual observation, aided by SYBR Green I dye. It, therefore, follows that LAMP assay can be developed for use on a single device or chip wherever and whenever needed. Presently, commercial LAMP kits are available. Japan has approved a LAMP kit used for identifying and monitoring disease agents.[@CIT0052]

LAMP is amenable to contamination quite easily, one reason being the number of pipetting steps and the use of multiple, specific primers. Performing LAMP, therefore, requires enormous care and strict adherence to aseptic techniques to prevent carryover contamination. Using DNA binding dyes for detection of amplified products preclude the opening of the reaction tubes post-amplification. Stains such as SYBR Green I, SYBR safe and calcein added to the reaction mixture before the amplification step, can aid visual detection of amplified products. Addition of Uracil-DNA-glycosylase (UDG-LAMP) before the amplification process has also been reported to prevent carryover contamination.[@CIT0053] In a two-step process, deoxyuridine triphosphate (dUTP) is added to all reaction mixtures for LAMP to enable incorporation of uracil to the resulting amplicons.[@CIT0048] In subsequent LAMP reactions, the addition of UDG to reaction mixtures ensures that uracil-containing LAMP amplicons from previous reactions are cleaved and degraded through hydrolysis at the phosphate backbone, leaving only the target DNA available for amplification. Heat is then used to deactivate the UDG enzyme. A second limitation of LAMP is the difficulty faced with multiplexing. The multiplex assay has not recorded as much success with LAMP as with PCR, due to the number of primers used.[@CIT0019] There is also the challenge of target selection and primer design. Appropriate targets could be missed by the software during the process, requiring manual intervention.[@CIT0054] False-positive amplification due to hybridisation by primers is also common.[@CIT0055] Hopefully, as the patent license (EP 1020534 B) for this technology expires in 2019, LAMP would experience more modifications. LAMP primers can be designed using software. Examples are the paid LAMP Designer ([<http://www.optigene.co.uk/lamp-designer/>]{.ul}) by OptiGene Limited (England), and PrimerExplorer (Version 5, [<https://primerexplorer.jp/e/>]{.ul}) provided free of charge by Eiken Chemical Company Limited (Japan).

Helicase-Dependent Amplification (HDA) {#S0002-S2002}
--------------------------------------

HDA was developed in 2004 and is a method that excludes the temperature cycling process necessary for the separation of double-stranded DNA (dsDNA). Instead, the DNA helicase enzyme separates the dsDNA. This separation facilitates primer annealing and elongation by polymerase enzyme.[@CIT0056] Helicase enzymes were found previously in *E. coli* in 1976.[@CIT0057],[@CIT0058] HDA is similar to the process of DNA replication in living organisms.[@CIT0026],[@CIT0059] The process begins when the helicase enzyme disrupts the hydrogen bonds of dsDNA and separates them using energy derived from ATP hydrolysis. The resulting single-stranded DNA (ssDNA) is covered by single-strand binding proteins (SSBs) which stabilise the strand and prevents reannealing between the two separated strands ([Figure 2](#F0002){ref-type="fig"}). Next, two primers bearing specific sequences anneal to the target regions on the ssDNA template. Extension by DNA polymerase enzyme takes place, leading to the addition of deoxynucleotide-triphosphates to produce two dsDNA. The resulting dsDNA undergo the same replication cycle, acting as templates. The first HDA assay was performed at 37°C and was able to amplify 10^3^ copies of genomic DNA by over ten million folds, in addition to being able to directly amplifying DNA in human blood.[@CIT0056] An existing patent (EP 1539979 B) for this technology will remain valid until 2023.Figure 2Helicase-dependent amplification. The process begins with strand separation by helicase, primer annealing, extension by polymerase and ends with two copies of the target. Adapted from Vincent M, Xu Y, Kong H. Helicase-dependent isothermal DNA amplification. *EMBO Rep*. 2004;5(8):795--800. Copyright © 2004 European Molecular Biology Organization.[@CIT0056]

HDA has undergone some improvements over the times. An et al[@CIT0060] achieved amplification at 60-65°C by replacing the UvrD helicase used in the first reported assay[@CIT0056] with a thermostable combination of MutL homologue and UvrD helicase of *Thermoanaerobacter tengcongensis*. The resulting HDA assay was more specific and sensitive than the first reported assay.[@CIT0060] HDA was further enhanced by fusing helicase enzyme with DNA polymerase. The resulting enzyme named as hemilase, increased the length of amplified fragments from the initial 70-120bp to 2.3 kilobases in the improved HDA.[@CIT0061] Goldmeyer et al[@CIT0062] developed and reported the first thermophilic HDA (tHDA) to be coupled with reverse-transcription in a single tube, which was able to successfully amplify Ebola virus-armored RNA target by up to one million-fold within 10 mins, in addition to detecting as low as 20 Enterovirus particles per reaction.[@CIT0062] A helicase dependent OnChip method which was able to identify *Staphylococcus aureus* resistant to methicillin (MRSA) and *Neisseria gonorrhoeae* in single and duplex reactions respectively has also been developed.[@CIT0063] This was achieved by detecting the *mec*A gene of *S. aureus* and the *piv~NG~* gene of *N. gonorrhoea*. Huang et al[@CIT0064] designed an electricity-free, sensitive HDA assay which was successfully applied to detect *Clostridium difficile* from 8 diarrhoea patients stool samples, with a detection limit of 1.25 x 10^−2^ pg. The disposable low-cost platform consisted of a thermoplastic reaction chip made with commercial toe warmers, insulated with Styrofoam. The design was reportedly cheaper and less material-consuming than other traditional methods.[@CIT0064] Amplified products from HDA can be visualised in real-time by fluorescence and by using agarose gel electrophoresis.[@CIT0026],[@CIT0056]

Some limitations of HDA include sample contamination, low reaction temperature, generation of non-specific amplification products due to primer mispairing and amplification inhibition.[@CIT0026],[@CIT0065] However, continuous improvement of HDA can surmount these problems. Primers for HDA can be designed using PrimerQuestSM^®^ provided by Integrated DNA Technologies (Coralville, USA).[@CIT0064] A report also used the Primer3 program for reverse transcription HDA (RT-HDA) primer design.[@CIT0062] Two versions of this program are now available: Primer3Plus ([<http://primer3plus.com>]{.ul}) and Primer3web ([<http://primer3.ut.ee/>]{.ul}).

Signal-Mediated Amplification of RNA Technology (SMART) {#S0002-S2003}
-------------------------------------------------------

The SMART technique which was first reported in 2001 by Wharam et al[@CIT0023] centres on amplified signals generated by the target sequence rather than direct amplification of target sequence and hence thermal cycling, or target sequence copying is not required.[@CIT0023] The method generates signals that are highly target-dependent, specific for different targets and can discriminate when there is a change in target-borne base pairs.[@CIT0066] The assay involves one oligonucleotide (single-stranded) probe for extending sequences and another that serves as the template. They both comprise a long end which anneals to the target and another shorter end with which they anneal to each other, only when the target sequence is present. When this happens, the two probes and the target form a three-way junction structure.[@CIT0023] Two different enzymes are involved in this method, namely T7 RNA polymerase and *Bacillus stearothermophilus* (Bst) DNA polymerase. A double-stranded promoter sequence of T7 RNA results when DNA polymerase synthesizes bases complementary to the single-strand (ss) of the opposite probe, thereby increasing the length of the extension probe ([Figure 3](#F0003){ref-type="fig"}). RNA signals are generated by T7 RNA polymerase only when the promoter sequence on the template probe becomes double-stranded (ds). RNA signal amplification occurs when the generated signal binds to another template oligonucleotide, from which DNA polymerase extension yields a double-stranded (ds) promoter. Additional rounds of RNA signal extension and transcription increases the generated signal, which can then be detected using a method known as enzyme-linked oligosorbent assay (ELOSA). An oligonucleotide linked with an enzyme and another labelled with biotin hybridises RNA signals in a sequence-specific manner to form a complex which is then captured in standard plate reader wells coated with streptavidin.[@CIT0023],[@CIT0067] The end detection system of the SMART method is by visualisation and measurement of the colour change that results in the well-contained solutions upon application of the substrate.[@CIT0067] Hence, this technique does not require gel electrophoresis and can simultaneously quantify multiple samples.Figure 3Signal-mediated amplification of RNA technology. A 3WJ forms; DNA polymerase extends the extension probe; T7 RNA polymerase promoter is formed, and T7 RNA polymerase generates signals (1st RNA). Signals can be transcribed by T7 RNA polymerase and detected by ELOSA (option 2) or further amplified to yield multiple 2nd RNA signals (option 1) which can then be detected. Adapted with permission from *Springer Nature.* Wharam SD, Hall MJ, Wilson WH. Detection of virus mRNA within infected host cells using an isothermal nucleic acid amplification assay: marine cyanophage gene expression within Synechococcus sp. *Virol J*. 2007;4(1):52.[@CIT0068]

Although SMART is not as sensitive as PCR, it has been reported to be more tolerant to samples of various types like genomic DNA and total RNA both in *E. coli*, crude cultures and non-target DNA.[@CIT0067] This technology has found application in detecting phage viruses of marine *Synechococcus*;[@CIT0066] differentiation of virus-infected hosts from healthy hosts by detecting gene expression;[@CIT0068] and detection of *coa* (coagulase) and *mec*A genes of MRSA. Since the signals generated by this method is the same for all targets, the technique can be incorporated into microbiological detection of any target once the three-way junction structure for the target sequence can be designed.[@CIT0069] Patents for the SMART assay include EP-B-0, 666.927, AU672367 and WO99/37806.[@CIT0023] There is currently no reported demonstration in the published literature regarding multiplexing capability of SMART.

Nucleic Acid Sequence-Based Amplification (NASBA) {#S0002-S2004}
-------------------------------------------------

Unlike SMART, NASBA is a method that centres on actual amplification of ssRNA and DNA. It is most suitable for detecting RNA targets such as messenger RNA, ribosomal RNA and genomic RNA.[@CIT0067],[@CIT0070],[@CIT0071] It is a method related to transcription-mediated amplification[@CIT0072] and self-sustained sequence replication (3SR) developed by Guatelli et al.[@CIT0073] It was first introduced in 1991[@CIT0022] and cannot be used for the amplification of double-stranded DNAs unless they are first denatured.[@CIT0059] NASBA requires only four to five cycles to achieve up to one million-fold amplification of RNA copies within 90 mins and does not require specialised equipment to perform.[@CIT0022],[@CIT0067] It works similarly to retroviral replication of RNA using complementary DNA intermediates ([Figure 4](#F0004){ref-type="fig"}). The process comprises three thermolabile enzymes, namely T7 DNA dependent RNA polymerase (DdRp), RNase H and avian myeloblastosis virus (AMV) reverse transcriptase, and requires two primers (P1 and P2). Two denaturation steps at 95°C are necessary to amplify a DNA target.[@CIT0071] Products amplified by the NASBA technique can be detected by gel electrophoresis,[@CIT0074] enzyme-linked gel assay (ELGA)[@CIT0075] and electro-chemiluminescence (ECL).[@CIT0076] NASBA-coupled molecular beacon for real-time detection of RNA[@CIT0077] has also been reported.Figure 4Nucleic acid sequence-based amplification. P1 anneals to sense RNA, then extension by AMV reverse transcriptase enzyme follows, forming a hybrid of RNA and complementary DNA (cDNA). P2 binds to cDNA following RNA degradation by RNase H; extension by reverse transcriptase generates DNA with T7 RNA polymerase promoter sequence, which transcribes into multiple antisense RNA (-) copies by DNA dependent RNA polymerase. P2 anneals to resulting RNA (-) strands, undergoes extension and forms hybrids of RNA (-) and cDNA. RNA (-) is degraded again by RNase H while P1 binds to the new cDNA, followed by extension by reverse transcriptase to yield dsDNA bearing promoter sequence for T7 RNA polymerase and the cycle continues, generating multiple RNA copies. Adapted from Zanoli LM, Spoto G. Isothermal amplification methods for the detection of nucleic acids in microfluidic devices. *Biosensors*. 2012;3(1):18--43.[@CIT0059]

NASBA is limited by the need for initial denaturation at a different temperature (65°C for RNA and 95°C for DNA) from the amplification reaction (41°C),[@CIT0059],[@CIT0071] and the need to add required thermolabile enzymes after the denaturation steps. Furthermore, amplification is efficient only with sequences that are 120--250 bp long. Despite these limitations, it is very suitable for diagnosis of RNA viruses and is less prone to contamination unlike PCR.[@CIT0078] Its low temperature of operation (41°C) is an advantage and speed of amplification (30 mins), coupled with the fact that unlike in PCR, primers used in the reaction does not significantly influence amplicon yield.

Different improvements and variants of NASBA have been developed with various applications. A commercial kit known as NucliSENS EasyQ System for HIV-1 RNA quantitation has been produced ([Table 2](#T0002){ref-type="table"}). It was capable of detecting and quantifying HIV-1 virus RNA in clinical samples.[@CIT0079] The use of real-time NASBA (RT-NASBA) to detect *Mycoplasma pneumoniae* has been reported, though with low sensitivity than conventional NASBA.[@CIT0080] Other published applications of NASBA include quantitative detection (NASBA-QT) of HCV,[@CIT0081] Rhinovirus,[@CIT0082] Human papillomavirus,[@CIT0083] Human Cytomegalovirus in HIV-1 positive patients,[@CIT0084] Hepatitis A,[@CIT0074] *Chlamydia trachomatis*,[@CIT0085] *Leishmania* parasites,[@CIT0086] and *Mycobacterium leprae*.[@CIT0087] Selective amplification of RNA signals by NASBA is unaffected by comparable DNA sequence when present.[@CIT0071] Further improvements have steered establishment of duplex[@CIT0088]--[@CIT0090] and multiplex[@CIT0088] NASBA for detecting various targets in non-clinical samples, in combination with different methods for detecting products.

NASBA, like other IA methods, has some limitations, a major one of which is the integrity of RNA recovered from samples for analysis. The labile nature of RNA could result in degradation and loss of viability in any event of delay between the time of collection, and assay performance.[@CIT0091] Also since the enzymes used are not thermostable, temperatures higher than 42°C can affect the enzymes and compromise the process. NASBA is also unlikely to efficiently amplify target sequences less than 100 bp and greater than 250 bp.[@CIT0071],[@CIT0092] Currently, there is no patent restriction on this IA method as the earlier patent has already expired.[@CIT0065]

Recombinase Polymerase Amplification (RPA) {#S0002-S2005}
------------------------------------------

Initially, RPA was developed with a probe-based method for detecting products. It is a method that uses the enzymes recombinase and DNA polymerase together with DNA-binding proteins to achieve DNA amplification. The proteins used in RPA are involved in the process of synthesis, recombination and repair of DNA within living organisms. The first report of RPA used the large fragment of *Bacillus subtilis* Pol I and T4 uvsX as DNA polymerase and recombinase respectively. DNA sample pre-treatment or thermal denaturation step is not required in RPA because recombinase enzyme facilitates the separation of dsDNA.[@CIT0093] Recombinase acts as a catalyst that facilitates the binding of oligonucleotide primers to target DNA templates of matching sequences. RPA begins when a primer bound to recombinase scans for specific complementary sequence on the dsDNA and hybridises to it, following the separation of the double-strand by recombinase enzyme ([Figure 5](#F0005){ref-type="fig"}). Upon proper binding of the primer to template DNA, the recombinase enzyme disengages from the complex, leaving the 3ʹ end open for the DNA polymerase enzyme to attach. The displaced DNA strand is then coated by DNA-binding proteins while primer extension by DNA polymerase forms a new dsDNA which acts as a template for an additional cycle of amplification. Repeated rounds of this process generate rapid target amplification, producing several copies of DNA. Gel electrophoresis and real-time fluorescence are methods for detecting amplified products of RPA.[@CIT0093]Figure 5Recombinase polymerase amplification. Recombinase-bound primers scan for complementary sequence; recombinase enzyme separates the strands and SSB proteins prevent reannealing of separated strands; primers anneal, and extension by DNA polymerase takes place, leading to the formation of two dsDNA. Repetition of this cycle produces multiple copies of DNA. Adapted from Piepenburg O, Williams CH, Stemple DL, Armes NA. DNA detection using recombination proteins. *PLoS Biol*. 2006;4(7):e204--e204.[@CIT0093]

The low-temperature requirement, coupled with simplicity of procedure and the ability of RPA to generate several copies of target DNA within a short time, makes it a suitable candidate method for incorporation into devices for disease diagnosis at points of care.[@CIT0091] Furthermore, RPA can be performed as a one-tube reaction with real-time detection, by including a fluorescent probe. Three kinds of fluorescent probes have been developed, namely the exo, nfo and fpg probes, which all contain a fluorophore and quencher.[@CIT0094] To aid primer design and solve problems associated with the process, a software known as Primer design for *RPA* (*PrimedRPA*) ([<https://omictools.com/primedrpa-tool>]{.ul}) which can automate the process of RPA primer and exo probe design is now available.[@CIT0095] It is designed to identify conserved regions and filter off parts capable of causing a cross-reaction during RPA and is a Python-based package. Some systems have been developed in a bid to making RPA an applicable on-demand testing method. These include digital RPA known as the slipchip[@CIT0096],[@CIT0097] and microchip;[@CIT0098] multiplex RPA for bacteria namely *Salmonella* spp and *Chronobacter* spp,[@CIT0099] *Listeria monocytogenes* and *Salmonella enterica* serotype Enteritidis,[@CIT0100] Group B streptococci;[@CIT0101] parasites (*Giardia, Cryptosporidium, and Entamoeba*)[@CIT0102] and fungus (*Botrytis cinerea, Pseudomonas syringae, and Fusarium oxysporum*);[@CIT0103] mobile RPA in a suitcase which was named diagnostics-in-a-suitcase (Dias);[@CIT0104],[@CIT0105] microfluidic integrated RPA;[@CIT0106]--[@CIT0109] and the one-step RPA assay.[@CIT0110] While a slip chip is microfluidic device lacking pumps and valves, a microchip contains pumps and valves that aid movement of sample and reaction reagents through channels linking reaction chambers. Although the initial patent (EP 0481065 B) over RPA has expired, patent rights still exist for some of the improvements it has experienced.

Some studies have reported the diagnosis of infectious diseases using RPA. Examples include in detecting and differentiating MRSA from MSSA, using multiplex RPA approach and lateral-flow strips.[@CIT0093] A lab-on-a-foil RPA system which consisted of a dry and liquid reagent microfluidic cartridge, a centrifugal analyser for incubation at 37°C and detection by real-time fluorescence, has been developed. The method successfully identified *S. aureus mec*A resistance gene.[@CIT0111] *Francisella tularensis*, which causes a zoonotic disease (tularemia) in both humans and animals has been successfully detected using a quantitative real-time RPA which showed a comparable result with PCR but was faster by 10 mins.[@CIT0112] Reverse transcription RPA (RT-RPA) has also been used to detect epidemic human Norovirus strain (GII.4 New Orleans).[@CIT0113] Yang et al[@CIT0114] used RPA with internal amplification control (RPA-IAC) to detect the *tox*R gene of *Vibrio parahaemolyticus* at a temperature of 37°C for 20 mins. Ahn and colleagues developed a paper chip single-step RPA for detecting foodborne pathogens.[@CIT0115] The method was able to simultaneously detect *S. aureus*, Shiga toxin-producing *E. coli* and *Salmonella typhimurium* at a low concentration (10^2^cfu/mL) in spiked milk, at 37°C for 20 mins. An RPA coupled with lateral flow strips (RPA-LF) for detection of *Coxiella burnetii* was successful at specifically detecting and differentiating the target organism from other bacteria within 30 mins, combining RPA at 37°C and lateral flow at room temperature.[@CIT0116] The RPA-LF had a sensitivity of 10 and 7 copies per reaction for plasmid and genomic DNA, respectively. Similarly, an RPA lateral flow dipstick (RPA-LFD) method has also been successfully used to detect the aquatic cyprinid herpesvirus 2 (CyHV-2) which causes diseases in fishes, in a process that is 50 mins faster and sensitivity 100 times greater than PCR, and without cross-reaction with other aquatic viruses.[@CIT0117] Rohrman and Richards-Kortum[@CIT0118] also reported a plastic and paper-made proof-of-concept device that couples RPA with enzymatic amplification of HIV DNA at a sensitivity of 10 DNA copies per microliter and amplification time of 15 mins.

Rolling Circle Amplification (RCA) {#S0002-S2006}
----------------------------------

RCA is an enzyme-based IA method. Its development was from the rolling circle replication that occurs naturally in many plasmids and viruses. It involves the amplification of short RNA or DNA primer from a circularised template DNA by RNA or DNA polymerase enzyme. The result of this amplification is a long ssDNA or ssRNA, which is composed of repeated sequences that are complementary to the dsDNA template and are adjacent to each other.[@CIT0119] The polymerase enzyme displaces the single strand of genetic material that results, while continuously amplifying the dsDNA template ([Figure 6](#F0006){ref-type="fig"}). This process continues until one or more factors such as depletion in nucleotide availability halt the process.[@CIT0091] RCA involves a DNA polymerase, a primer (RNA or DNA), a target (circular) and deoxynucleotide triphosphates (dNTPs). RCA uses enzymes such as Phi29, Bst, and Vent *exo*-DNA polymerases, but Phi29 DNA polymerase is most preferred.[@CIT0119] This is due to its high strand displacement, and ability to process very complex circular DNA templates such as those having organisational issues, multiple cross-overs and multiple branches. RCA products can be detected using gel electrophoresis[@CIT0120]--[@CIT0122] or visually using fluorescence spectroscopy, microscopy and flow cytometry.[@CIT0123]--[@CIT0127] Furthermore, incorporating nanoparticles such as gold nanoparticles (AuNPs), magnetic beads, and quantum dots into RCA products[@CIT0128]--[@CIT0130] can aid the visualisation of products. Primers designed for PCR can be used for RCA.[@CIT0067]Figure 6Rolling circle amplification. \[**1**\] Primer anneals to circular DNA which is continuously extended by polymerase enzyme to produce a displaced long ssDNA with tandem repeat sequences. Adapted with permission from Liu D, Daubendiek SL, Zillman MA, Ryan K, Kool ET. Rolling Circle DNA Synthesis: Small Circular Oligonucleotides as Efficient Templates for DNA Polymerases. *J Am Chem Soc*.1996;118(7):1587--1594. Copyright 1996 American Chemical Society.[@CIT0203] \[**2**\] Hyper-branched RCA in which more than one primer anneals to products of previous amplification or padlock probe is used to form a circular DNA. New strands arise from the extension of primers; as they are displaced, reverse primers anneal and are extended to generate more displaced strands, resulting in multiple copies of highly branched DNA. Adapted from Yan J, Zhou Y, Zheng AS, et al. Isothermal amplified detection of DNA and RNA.  *Mol. BioSyst.* 2014;10:970-1003.[@CIT0070] \[**3**\] Multiprimed RCA or multiply primed RCA in which multiple primers anneal to different points on a circular DNA with simultaneous extension and displacement. Multiply-branched structures result. Adapted with permission from Dean FB, Nelson JR, Giesler TL, Lasken RS. Rapid amplification of plasmid and phage DNA using Phi29 DNA polymerase and multiply-primed rolling circle amplification. *Genome Res*. 2001;11(6):1095--1099.[@CIT0134] Copyright © 2001, Cold Spring Harbor Laboratory Press.

Since its discovery in the mid-1990s, RCA has undergone some modifications.[@CIT0119] RCA initially utilised only circular ssDNA target as a template but not linear double-stranded targets.[@CIT0059] The design of oligonucleotides known as padlock probes,[@CIT0131] containing 3ʹ- and 5ʹ sequences that can bind with a target sequence with both ends have solved the problem. The probe becomes circularised when the ends are joined together by ligase. Long DNA sequences with tandem repeats can then be synthesised from this circularised padlock probe once a primer binds to it. A polymerase enzyme then amplifies the primer.[@CIT0070] The ligation process can be achieved either by using a template or without a template. Template mediated ligation can be achieved using the T4 DNA ligase while template-free ligation can be achieved using a special DNA ligase known as CircLigase.[@CIT0119],[@CIT0132],[@CIT0133]

One of the attributes that set this method apart is the exponential amplification of target material using RCA. By a process known as multiprimed RCA or multiply-primed RCA, it is possible to apply more than one primer at a time to achieve amplification from multiple points on the same circular template. After primer annealing, DNA polymerase begins the extension of the primers with the successive displacement of newly synthesised strands. Primers further anneal to the displaced strands and elongation by DNA polymerase continues, resulting in the formation of a multiple-branched structure.[@CIT0119],[@CIT0134] A second method is known as the hyper-branched RCA (HRCA), in which a padlock probe is used at the start.[@CIT0135],[@CIT0136] Upon successful elongation of the primer by the polymerase enzyme, the resulting displaced linear products from the RCA are annealed to, by subsequent sets of reverse primers, which are further extended by DNA polymerase, and displaced once the end of an adjourning primer is reached. Multiple copies of highly branched DNA result from the repetition of the process with newly displaced single-stranded products. This RCA method is also known as ramification amplification (RAM)[@CIT0136] or cascade RCA.[@CIT0137]

RCA possess some features that make it a suitable tool for some fields. For instance, it does not require temperature regulation as is done in PCR and could be performed in a liquid, on a solid, in vitro and in vivo. Also, detecting a single molecule using RCA is possible due to its adaptability either on a solid support or inside a cell such as in the identification of surface protein markers on tumour cells[@CIT0138] and measurement of protein levels in serum samples.[@CIT0139] Since RCA products contain repeated sequences, the technique can be customised or tailored towards desired sequences by manipulating the template. In addition to all these, amplification by this method is considered efficient, with multivalent capabilities.[@CIT0119]

Although not much data appears to be available, RCA has been used in the diagnosis of some disease-causing agents. RCA designed with stem-loop primer has been used to detect HPV16 and HPV18 from carcinoma cells of the cervix, and cervical mucus exfoliated cell samples.[@CIT0128] Similarly, H5N1 influenza virus detection using hyperbranched RCA with a detection limit of 9fM has been reported.[@CIT0122] The authors reported that results obtained by RCA compared favourably to standard real-time PCR. Juul and colleagues[@CIT0140] reported a microfluidics RCA known as rolling-circle enhanced enzyme activity detection (REEAD) for detecting *Plasmodium*. In this protocol, topoisomerase I (pTopI) of the *Plasmodium* performs the required circularisation of the RCA substrate. Crude clinical samples could be detected using REEAD with high sensitivity.[@CIT0059] RCA assays can be completed with amplification of products ≤90 mins.[@CIT0122],[@CIT0135],[@CIT0141]

As a limitation to this IA method, linear multimeric by-products can arise during ligation steps of the test.[@CIT0133] Inadequate binding sites for enzymes also hamper the effectiveness of ligation by enzymes, especially for small DNA.[@CIT0142] Long storage of RCA products results in non-specific cross-linking within and between component molecules, making mass production and storage of RCA systems a difficult venture. The problem of cross-linking between components can be minimized by fine-tuning parameters such as length of product formed, the sequence used and composition of the RCA assay. The use of a computer-aided application such as the cadnano to design and construct predictable DNA nanostructures has also been suggested to minimise non-specific interactions during RCA.[@CIT0119]

Strand Displacement Amplification (SDA) {#S0002-S2007}
---------------------------------------

SDA is the IA method that gave rise to multiple displacement amplification and LAMP. It was first reported in 1992 by Walker et al[@CIT0024] and syndicates activity of an exonuclease-deficient DNA polymerase with a restriction endonuclease *Hinc*II and in combination with four different primers. The first two S~1~ and S~2~ primers contain restriction enzyme recognised sites at the 5ʹ end to the target complementary sequence, while the other two B~1~ and B~2~ primers are known as the bumper primers.

SDA begins with an initial denaturation step at 95°C to separate the double-stranded DNA to allow annealing between each strand and one each of the primers ([Figure 7](#F0007){ref-type="fig"}). The primers S~1~ and S~2~ are extended to produce a strand bearing restriction sites for endonuclease activity. These strands are each displaced by bumper primers B~1~ and B~2~ respectively, resulting in double-stranded DNAs and displaced single strands from S~1~ and S~2~ extensions. S~1~ and B~1~ extension, as well as S2 and B2, are done simultaneously by exo-klenow in the presence of dGTP, dCTP, TTP and thiol-modified dATP (dATPαS). In the following reactions, B~2~ and S~2~ anneal to S~1~ extension, while B~1~ and S~1~ anneal to S~2~ extension, followed by extension and displacement steps as in the previous step, giving rise to two fragments with hemiphosphorothioate *Hinc*II site on both ends and another pair bearing it only on one end. The newly synthesised DNA strands thus, incorporate the modified dATP and is hence, inactive to the endonuclease enzyme.Figure 7Strand displacement amplification. Denaturation of a dsDNA allows annealing of primers S1, S2, B1 and B2 which are extended simultaneously with the displacement of extended S1 and S2 strands bearing *Hinc*II restriction sites. When a dsDNA with both strands bearing *Hinc*II restriction sites is generated, the unmodified original strand extended from the primers is nicked by the enzyme, while the polymerase extension of the 3ʹ end of the newly synthesized strand results in the displacement of downstream DNA strands. The displaced strands then form the template for subsequent amplification which results in exponential amplification of the target. Adapted with permission from Walker TG. Empirical Aspects of Strand Displacement Amplification. *Genome Res*. 1993; 3:1--6.[@CIT0204] Copyright © 1993, Cold Spring Harbor Laboratory Press.

This round of annealing and extension continues until a dsDNA with both strands bearing *Hinc*II restriction sites result. The strands are then nicked by the endonuclease enzyme, followed by polymerase extension of the strand at the nick, leading to multiple circles of nicking, extension and displacement. The endonuclease nicks the unmodified original strand extended from the primers, while the polymerase extension occurs at the 3ʹ end of the newly synthesised strand to displace DNA down the strand. The displaced strands then form the template for subsequent amplification which culminate to more rapid target amplification.[@CIT0024],[@CIT0143] SDA product detection is possible by methods such as gel electrophoresis,[@CIT0144]--[@CIT0146] molecular beacons[@CIT0145],[@CIT0147] and fluorescence methods.[@CIT0148]--[@CIT0150]

SDA has been applied in the diagnosis of tuberculosis through reverse-transcriptase SDA.[@CIT0144] The technique which targeted alpha-antigen (85B protein) of *Mycobacterium tuberculosis* was successful at detecting and monitoring mRNA presence in patients undergoing tuberculosis treatment over 14 days, with an analytical sensitivity of 10 copies of target. Commercial kits for SDA ([Table 2](#T0002){ref-type="table"}) are also available.

An example is the BD ProbeTec^TM^ ET system designed for detecting *Chlamydia trachomatis* in urine[@CIT0145],[@CIT0151] and *Neisseria gonorrhoea* in urine.[@CIT0152] Clinical studies on patient urine and swab samples with the developed SDA-based assay reported a sensitivity of 100% and specificity of 100% for detection of *C. trachomatis* and *N. gonorrhea* nucleic acid[@CIT0145] while another reported a specificity of 99.2% and sensitivity of 99.3% for *N. gonorrhoea* using BD ProbeTec^TM^ SDA system on urine samples, in which results were obtained in less than 5 hrs with better performance than culture method.[@CIT0152] Similarly, Van Der Pol et al[@CIT0153] reported sensitivity ranging from 80.5% to 98.5% when this assay was used to detect chlamydia and gonorrhoea infection in men and women using urine, cervical and urethral swabs. The reported BD ProbeTec^TM^ ET system incorporates SDA with real-time fluorescence detection.

Despite the exponential nature of amplification by SDA, the method is limited by the inability to amplify base-pair sequences that are longer than 50 bp to 120 bp.[@CIT0067] There also appears to be very little known about the development of simple SDA for use at patient point of care and research purposes, probably due to the long-time required for running this method.[@CIT0091] A recent application of SDA has been in the detection of microRNAs.[@CIT0154] Dickinson and Company was assigned patent right to this IA technique in 1995, but the patent right now bears an expired status as at 2019.

Multiple Cross Displacement Amplification (MCDA) {#S0002-S2008}
------------------------------------------------

MCDA is a new IA method that was first reported in 2015 by Wang et al[@CIT0025] It involves only one enzyme, a polymerase with strand displacement capability and is isothermal, operating at a single temperature throughout the reaction (between 60 -- 68°C). It is also reported to be highly sensitive, specific and can be applied to rapid biological, environmental and clinical research. The reaction completes in less than 40 mins. Amplification by this method involves the use of 10 primers which are the amplification primers, cross primers and displacement primers. The primers include C1, C2, D1, D2, R1 and R2 which identify target sites C1s, C2s, D1s, D2s, R1s and R2s; F1 and F2 are the displacement primers, while the cross primers are CP1 and CP2 which respectively identify F1s, F2s, P1s and P2s. In the first step of the MCDA, CP1 anneals to P1s and extends, while the new strand is displaced by that synthesised from F1 extension ([Figure 8](#F0008){ref-type="fig"}). In step 2, C1, D1, F2, R1 and CP2 anneal to the displaced strand and are simultaneously extended to generate four different products, namely C1, R1, D1 and CP2. Extension of product D1 by primers C1 and CP1 results in a new product CP1/C1, while the C1 product forms an intramolecular stem-loop due to its complementary C1s sequence at its 3ʹ end and C1 sequence at its 5ʹ end. This stem-loop is then extended by CP1 to generate another product CP1/C1 of two strands which can reanneal to form loop structures stabilised by C1 and C1s base-pair double helix. These two strands can become templates for amplification by D1, C1 and CP1 to form products CP1/D1 and CP1/C1 respectively as in the first circle. In the second cycle of MCDA, the second product from step 2 (R1) undergoes a similar amplification process as C1 to yield products CP1/C1, CP1/D1, CP1/R1 and R1/R1s, respectively. The product CP2 from step 2 resulting from displacement by F2 primer can also form a stem-loop when extended, owing to complementary sequences on its 3ʹ and 5ʹ ends. Primers C2, D2 and R2 then anneal to this newly formed strand and a process similar to that of C1, D1 and R1 are repeated. The stem-loop structures formed over series of steps from these two cycles of amplification become templates in the exponential amplification cycle and undergo series of amplification and displacement reactions to yield multiple copies of the target DNA bearing inverted repeats.[@CIT0025]Figure 8Multiple cross displacement amplification. CP1 anneals to P1s to begin the reaction. Synthesis by F1 displaces the product formed by CP1, which is then annealed to by amplification primers D1, C1, R1, CP2 (cross primer) and F2 (displacement primer), leading to four different products (step 2). A new product CP1/D1 is formed by the extension of product D1 by C1 and CP1 (step 3), while the C1 product forms an intramolecular stem loop due to complementarity at its 3ʹ (C1s sequence) and 5ʹ (C1 sequence) ends. CP1 extends the stem loop, forming a new CP1/C1 product (step 4). These can then become templates from which amplification primers D1, C1 and CP1 generate products CP1/D1 and CP1/C1 respectively as before (Cycle 1). In cycle 2, product R1 undergoes a similar amplification process as C1 to yield products CP1/C1, CP1/D1, CP1/R1 and R1/R1s respectively. CP2 product displaced by F2 primer from step 2, is extended at the 3ʹ end to form a new double strand with stem loop structure (step 6). Primers C2, D2 and R2 then anneal to the newly formed strands to repeat similar form of amplification by C1, D1 and R1 (step 8). The two cycles generate several stem loop structures which become templates for exponential amplification to yield multiple copies of the target DNA with numerous inverted repeats. Reproduced with permission from Wang Y, Wang Y, Ma A-J, et al. Rapid and sensitive isothermal detection of nucleic-acid sequence by multiple cross displacement amplification. *Sci Rep.* 2015;5:11902.[@CIT0025]

Products of MCDA amplification can be visualised by gel electrophoresis and colourimetric methods[@CIT0025],[@CIT0155] and also lateral flow biosensor,[@CIT0155]--[@CIT0158] nanoparticles based biosensor[@CIT0155],[@CIT0159] and real-time turbidity.[@CIT0155] Primer design for MCDA uses software used for LAMP and PCR primer design which are PrimerExplorer (Eiken Chemical Company limited, Japan)and Primer Premier (Premier Biosoft International, USA).[@CIT0157]

One major setback of this method is the generation of false-positive results due to the formation of primer-dimers and off-target hybrids, as well as problems of low sensitivity, high background and loss of signals that result when the primers and polymerase mix with triphosphates.[@CIT0155],[@CIT0160] Efforts made towards improving the method and solving these problems since its development, includes the development of self-avoiding molecular recognition system (SAMRS) assisted MCDA or SAMRS-MCDA. The SAMRS-MCDA system operates at 60°C and visualisation of products is by a lateral flow biosensor coupled with nanoparticles. Primers made up of self-avoiding molecular recognition system components, enables selective hybridisation to nucleotides apart from other SAMRS-containing sequences.[@CIT0155]

MCDA and SAMRS-MCDA have been successfully used to detect disease-causing bacteria such as *Shigella* species,[@CIT0158] *Vibrio parahaemolyticus*,[@CIT0157] *Listeria monocytogenes*,[@CIT0160] *Klebsiella pneumonia*,[@CIT0159],[@CIT0161] *Pseudomonas aeruginosa*,[@CIT0155] *S. aureus* and MRSA by the *mec*A and *nuc* genes as targets.[@CIT0156] A multiplex MCDA was also successfully used to distinguish between MRSA, MSSA and non-*S. aureus*. There have been reports of impressive specificity and sensitivity for MCDA in the mentioned studies with detection of target organisms from samples such as sputum,[@CIT0159],[@CIT0161] blood,[@CIT0156] oyster,[@CIT0157] and faeces.[@CIT0158] With results from the mentioned studies comparable to established methods, MCDA could serve as a valuable on-the-spot diagnostic tool for rapidly detecting disease agents specifically in areas with resource constraints, giving its simplicity and cost-effectiveness.[@CIT0157]--[@CIT0159] Wang et al[@CIT0025] have since applied for a patent of their novel methodology and sequences covered in their earlier work at the State Intellectual Property Office of the People's Republic of China (application number CN201510280765.X).

Miniaturising IA for POC Use {#S0003}
============================

An efficient testing system suitable for clinical application should be condensable into a simple point-of-care device with the most minimal technical expertise. A number of these IA techniques for which POC devices have been attempted are still at the proof-of-concept-stage. Such an ideal diagnostic method should be able to operate without sophisticated equipment, should combine preparation of the sample, amplification and product detection all in one, and still retain specificity, sensitivity, simplicity, robustness and cost-effectiveness.[@CIT0065]

Microfluidic systems are those that utilise only a minimal volume of sample, usually in microlitres. This property makes contamination most unlikely and allows miniaturisation of equipment, thus making them very suitable for POC applications, especially in resource-constrained environments. They employ microchambers free of fluids and as such are simpler, energy-saving systems, not requiring heating and cooling systems, or fluid recycling.[@CIT0162] Valves, mixers and pumps can also be integrated, enabling the regulation of fluids and other device components. The flow of fluids in microfluidics can either be passive by diffusion or active by application of some external force that increases the diffusion rate. These have been used to achieve droplet-based and continuous flow technologies for controlling fluids in microfluidic devices.[@CIT0163] Microfluidic devices comprise of materials such as nitrocellulose, glass fibre, cellulose, paper and silicon, with paper and polymers being the most popular.[@CIT0065] A microfluidic device based on NASBA detected amplification using fluorescent measurements with a detection limit of 5 fmol/l has been reported.[@CIT0164] Paper-based devices have been used successfully in diagnostic assays based on colourimetric chemical detection and immunoassay of proteins, which probably informed the use of paper for IA devices. Kaarj et al[@CIT0165] used RT-LAMP based paper microfluidic chip for detection of Zika Virus from human urine and plasma samples. The device achieved a sensitivity as low as one copy/µL, and real-time quantification by smartphone imaging. Similarly, a paper-based RT-RPA microfluidic device designed by Magro et al[@CIT0166] for Ebola virus was tested on the field in Guinea, with reported 90% sensitivity to PCR, with multiplexing capability. The device used reagents freeze-dried on paper. Rohrman and Richards-Kortum reported an isothermal enzymatic amplification of DNA from HIV, using a lateral flow device with low-cost, light-weight for POC testing with DNA extracted from dried blood spots.[@CIT0118] A more recent report, however, described more efficient amplification when polyethersulfone and polycarbonate were used for LAMP and HDA, instead of cellulose paper, glass fibre, or nitrocellulose. Polyethersulfone though not widely applied in rapid diagnostic assays, proved to be a better material for rapid POC application with nucleic acid from *Bordetella pertussis, Chlamydia trachomatis, Neisseria gonorrhoeae*, and Influenza A H1N1.[@CIT0167]

One major challenge of microfluidic devices is that of biomolecular interactions with the walls of microfluidic channels, which can reduce enzyme and primer concentrations, thereby resulting in reaction inhibition. However, the use of polyethersulfone may be more expensive for application than cellulose. Applying surface treatment (eg using polyethersulfone) to hydrophilic materials could solve the problem of non-specific adsorption of reaction components usually associated with surfaces.[@CIT0065] Surface coatings can come as permanent modifications such as using polyethene glycol (PEG) or blocking well surfaces with molecules such as bovine serum albumin. Problems also arise when micro-devices are poorly fabricated, leading to the presence of rough surfaces, junctions and sharp corners, all of which can reduce the concentration of biomaterials available for the reaction.[@CIT0162] Several methods available for fabrication of microfluidics include injection moulding, microthermoforming, hot embossing, casting, lithography and laser ablation.[@CIT0168] Hence, miniaturisation of IA into POC devices requires careful consideration of materials used in fabrication, as well as the method of fabrication to be used, in other to achieve efficient microfluidic devices.

Prospects of Isothermal Amplification {#S0004}
=====================================

Given the increasing acceptance and application of isothermal methods for amplification of nucleic acids and detection of pathogenic microbes ([Table 1](#T0001){ref-type="table"}), it is sufficient to project an isothermal-based diagnostic world soon. Notwithstanding the improvements recorded in the development and application of isothermal diagnostic assays to infectious disease diagnosis, some other methods are being established as fresh innovations or off-shoots of already existing technologies. Some of these include exponential amplification reaction (EXPAR),[@CIT0169] single chimeric primers isothermal amplification (SPIA),[@CIT0170] Isothermal and chimeric primer-initiated amplification of nucleic acids (ICAN),[@CIT0171] hairpin fluorescence probe assisted isothermal amplification[@CIT0172] and beacon-assisted detection amplification.[@CIT0173] Also, there appears to be the need for standardization of these methods as contrasting data exist regarding the performance of some of these methods, thereby making comparison difficult.[@CIT0091] The nearest future should witness more compact hand-held diagnostic technologies that operate on isothermal principles and still combine such simplicity with accuracy and rapidity. This advancement could positively alter the current state of healthcare in developing countries where the accurate diagnosis of diseases is still a huge problem while making diagnosis faster in developed countries. Winning the fight against the impact of diseases especially in resource-constrained societies requires simple, rapid, but yet sensitive diagnostic tests to be available for clinical application.

Conclusion {#S0005}
==========

Rapid and accurate identification of disease agents is key to achieving good health and managing the ravaging effects of pathogens. Developing and improving already existing technologies is at the heart of this drive, and isothermal technologies hold a large stake, owing to characteristics such as simplicity, cost-effectiveness, robustness, sensitivity and specificity. In some cases, these methods have been reported to perform even better than PCR and other previously existing traditional diagnostic methods, which are more cumbersome and demanding in their application. Tailoring these methods to meet the massive and urgent diagnostic gap in resource-limited environments and developing countries could be easier to achieve than employing the use of culture-based methods and other more expensive and high skill-demanding techniques. Despite the huge potentials of these isothermal methods, some are yet to be commercialised or developed for clinical diagnosis at treatment points. Hence, it is important to develop hand-held technologies that will make isothermal diagnostic methods easily accessible and more suitable for use at point-of-care. For instance, improving the multiplexing ability and incorporating preparation of samples, purification steps and product detection into one simple step would increase the fortunes of isothermal methods in diagnostics. Isothermal methods with multiplexing capability would record higher application because it would translate to more efficient usage, arising from the liberty of processing multiple samples for multiple targets simultaneously. Thus, time, resources and energy will be saved and diagnosis-to-treatment time drastically reduced. Future improvements should also target rapid detection of resistance genes up to multiplexing levels, as most of the methods have only demonstrated identification of pathogens. Such an improvement would greatly strengthen the success of the fight against antimicrobial resistance and its attendant problems in disease treatment and management.
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[^1]: **Abbreviations:** IA, Isothermal amplification; TTR, Time to result; LOD, Limit of detection; GS, Gold standard; PPV, Positive Predictive Value; NPV, Negative Predictive Value; NC, Not computed in the publication; ND, Not documented; RT, Real time; *ge*, Genome equivalent; p/mL, Parasites per microliter; Dil, Dilutions; Ref., Reference; cfu, Colony forming units.

[^2]: **Abbreviations:** POC, Point of care use; LAMP, Loop-mediated isothermal amplification; NASBA, Nucleic acid sequence-based amplification; SDA, Strand displacement amplification; HDA, Helicase dependent amplification; TMA, Transcription-mediated amplification.
